

RECEIVED

OCT 08 2002

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99 OMB 0651-0031
U.S. GOVERNMENT PRINTING OFFICE: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2000

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number 09/981,845

Filing Date

October 18, 2001

First Named Inventor

Samy Ashkar

Group Art Unit

1644

Examiner Name

M. M. Haddad

Attorney Docket Number

CMCC 779

RECEIVED

SEP 15 2002

3700

OTHER ART -- NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. ¹
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
AM	ALBREKHTSSON, et al, "The Interface Zone of Inorganic Implant In Vivo: Titanium Implants in Bone," <i>Acta Biomater</i> , 1-27 (1983).
	BAGAMBISA, et al. <i>Int. J. Oral Maxillof. Impl.</i> 5: 217-226, 1994.
	BORYSIEWICZ, et al., "Isoform of human osteopontin in protein," <i>EMBL: XP-002201345</i> , May 14, 1990.
	BOWERS, et al., "Optimization of Surface Micromorphology for Enhanced Osteoblast Responses In Vitro," <i>Int. J. of Oral and Max. Imp.</i> 7(3): 302-310 (1992).
	BUTLER, "The Nature and Significance of Osteopontin," <i>Connect. Tissue Res.</i> 23(2-3): 123-136 (1989).
	CANTOR, et al., "Recombinant activation protein-1," <i>EMBL: XP-002201347</i> , January 10, 1990.
	GALANTE, et al., "The Biologic Effects of Implant Materials," <i>J. Ortho. Res.</i> 9(5): 760-775 (1991).
	GERSTENFELD, et al., "Expression of Differentiated Function by Mineralizing Cultures of Chicken Osteoblasts," <i>Develop. Biol.</i> 122(1): 49-60 (1987).
	GROESSNER-SCHREIBER, et al., "Enhanced Extracellular Matrix Production and Mineralization by Osteoblasts Cultured on Titanium Surfaces In Vitro," <i>J. Cell Sci.</i> 101(1): 209-217 (1992).
	LEGEROS, et al., "Strategies to Affect Bone Remodeling: Osteointegration," <i>J. Bone Miner. Res.</i> 8(S2): S583-S593 (1993).
AM	LIAN, et al., "Concepts of Osteoblast Growth and Differentiation: Basis for Modulation of Bone Cell Development and Tissue Formation," <i>Crit. Rev. Oral Biol. Med.</i> 3(3): 269-305 (1992).

Examiner's
Signature

REQUAYM 10/02

Date Considered

8/15/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.1 Unique citation designation number.² See attached Kinds of U.S. Patent Documents.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).⁴ For Japanese patent documents, the indication of the year or the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible.⁵ Applicant to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
TECHNOLOGY CENTER R3700

ATL1 #544401 v1

Paper No. 6
CMCC 779
078856/00047



Please type or sign (+) inside this box →

Under the Patent Law Reduction Act of 1995, no persons are required to respond to a collection of information if it does not display a valid control number.

Substitute for form 1449A/PTO

RECEIVED

OCT 08 2002

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1800/2000

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	09/981,845	RECEIVED
Filing Date	October 18 2001	TECH CENTER 1800/2000
First Named Inventor	Samy Ashkar	700
Group Art Unit	1644 1647	700
Examiner Name	M. M. Haddad R. DeBenedictis	700
Attorney Docket Number	CMCC 779	700

OTHER ART - NON-PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, serial, symposium, catalog, etc.), date (page(s)), volume-issue number(s), publisher, city and/or country where published
KM	MURTY, et al., "Sulfation In Vitro of Mucus Glycoprotein by Submandibular Salivary Gland: Effects of Prostaglandin and Acetylsalicylic Acid," <i>Biochim. Biophys. Acta</i> 968: 287-296 (1988).	
	O'NEAL, et al., "Biological Requirements for Material Integration," <i>J. Oral Implantol.</i> 18(3): 243-255 (1992).	
	OWEN, et al., "Progressive Development of the Rat Osteoblast Phenotype In Vitro: Reciprocal Relationships in Expression of Genes Associated with Osteoblast Proliferation and Differentiation During Formation of the Bone Extracellular Matrix," <i>J. Cell. Physiol.</i> 143(3): 420-430 (1990).	
	PARSEGAN, "Molecular Forces Governing Tight Contact Between Cellular Surfaces and Substrates," <i>J. Prosthet. Dent.</i> 49(6): 838-842 (1983).	
	RUTHERFORD, et al., "Use of Bovine Osteogenic Protein to Promote Rapid Osseointegration of Endosseous Dental Implants," <i>Int. J. Oral Maxillofac. Imp.</i> 7(3): 297-301 (1992).	
	SENGER, et al., "Adhesive Properties of Osteopontin: Regulation by a Naturally Occurring Thrombin-Cleavage in Close Proximity to the GRGDS Cell-Binding Domain," <i>Mol. Biol. Cell</i> 5(5): 565-574 (1994).	
	SENGER, et al., "Cell Migration Promoted by a Potent GRGDS-Containing Thrombin-Cleavage Fragment of Osteopontin," <i>Biochim. et Biophys. Acta</i> 1314: 13-24 (1996).	
	SHEN, "Organic Extracellular Matrix Components at the Bone Cell/Substratum Interface," <i>Cells and Materials</i> 3(3): 257-272 (1993).	
	SMITH, et al., "Osteopontin N-Terminal Domain Contains a Cryptic Adhesive Sequence Recognized by α 5 β 1 Integrin," <i>J. Biol. Chem.</i> 271(45): 28485-28491 (1996).	
	STRAUSS, et al., "Gene Expression During Osteogenic Differentiation in Mandibular Condyles In Vitro," <i>J. Cell. Biol.</i> 110(4): 1369-1378 (1990).	
KM	"Synthetic fusion protein SA341-1," <i>EMBL</i> : XP-002201348, April 23, 1993.	

RECEIVED

Date Considered:

OCT 1 - 2002

Examiner's Signature

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant." TECH CENTER R3700

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Paper No. 6

OCT 08 2002

TECH CENTER 1600/2000

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

RECEIVED

SEP 25 2002

TECHNOLOGY CENTER 1600

SEP 27 2002

TC 1600

SEP 27 2002

700

2002



Sheet

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

09/981,845

Filing Date

October 18, 2001

First Named Inventor

Samy Ashkar

Group Art Unit

1641 (164)

Examiner Name

M. M. Haddad

Attorney Docket Number

CMCC 779

4

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

4

of

4

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

TERMINI, "Sequence of human osteopontin II," EMBL XP-002201346, October 9, 1990.

UNIYAL, et al., "Patterns of Adsorption of Proteins from Human Plasma onto Foreign Surfaces," Thromb. Haemost. 47(3): 285-290 (1982).

VAN DUK, et al., "Evidence that a Non-RGD Domain in Rat Osteopontin is Involved in Cell Attachment," J. Bone Min. Res. 8(12): 1499-1505 (1993).

WEBER, et al., "Receptor-Ligand Interaction between CD44 and Osteopontin (Eta-1)," Science 271(5248): 509-512 (1996).

XIANG, et al., "The Effect of Bone Morphogenetic Protein on Osseointegration of Titanium Implants," J. Oral Maxillofac. Surg. 51(6):647-651 (1993).

ZOHAR, et al., "Single Cell Analysis of Intracellular Osteopontin in Osteogenic Cultures of Fetal Rat Calvarial Cells," J. Cell. Physiol. 170(1):88-100 (1997).

Examiner's

Signature

REEXAMINER: Initial if reference considered, whether or not citations in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.